ERBB2 and breast cancer: Gene-Expression Signature (GES) for instance can now be used to decipher the heterogeneity of BC, and are used in many countries for chemotherapy decisions in estrogen-receptor-positive (ER+), HER2-negative (HER2−) early BC [4].